Department of Cardiology, School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University, #1665, KongJiang Road, Shanghai, 200092, China.
BMC Cardiovasc Disord. 2022 Aug 6;22(1):360. doi: 10.1186/s12872-022-02742-2.
Adaptive cardiac resynchronization therapy (aCRT) is associated with improved clinical outcomes. Left bundle branch area pacing (LBBAP) has shown encouraging results as an alternative option for aCRT. A technique that can be accomplished effectively using LBBAP combined with coronary venous pacing (LOT-aCRT). We aimed to assess the feasibility and outcomes of LOT-aCRT.
LOT-aCRT, capable of providing two pacing modes, LBBAP alone or LBBAP combined with LV pacing, was attempted in patients with CRT indications. Patients were divided into two groups: those with LBBAP and LV pacing (LOT-aCRT) and those with conventional biventricular pacing (BVP-aCRT).
A total of 21 patients were enrolled in the study (10 in the LOT-aCRT group, 11 in the BVP-aCRT group). In the LOT-aCRT group, the QRS duration (QRSd) via BVP was narrowed from 158.0 ± 13.0 ms at baseline to 132.0 ± 4.5 ms (P = 0.019) during the procedure, and further narrowed to 123.0 ± 5.7 ms (P < 0.01) via LBBAP. After the procedure, when LOT-aCRT implanted and worked, QRSd was further changed to 121.0 ± 3.8 ms, but the change was not significant (P > 0.05). In the BVP-aCRT group, BVP resulted in a significant reduction in the QRSd from 176.7 ± 19.7 ms at baseline to 133.3 ± 8.2 ms (P = 0.011). However, compared with LOT-aCRT, BVP has no advantage in reducing QRSd and the difference was statistically significant (P < 0.01). During 9 months of follow-up, patients in both groups showed improvements in the LVEF and NT-proBNP levels (all P < 0.01). However, compared with BVP-aCRT, LOT-aCRT showed more significant changes in these parameters (P < 0.01).
The study demonstrates that LOT-aCRT is clinically feasible in patients with systolic heart failure and LBBB. LOT-aCRT was associated with significant narrowing of the QRSd and improvement in LV function.
适应性心脏再同步治疗(aCRT)可改善临床结局。左束支区域起搏(LBBAP)已被证明是 aCRT 的一种替代选择,具有令人鼓舞的效果。可以使用 LBBAP 联合冠状静脉起搏(LOT-aCRT)有效地完成一种技术。我们旨在评估 LOT-aCRT 的可行性和结果。
在有 CRT 适应证的患者中尝试 LOT-aCRT,该技术可提供两种起搏模式,单独 LBBAP 或 LBBAP 联合 LV 起搏。患者分为两组:接受 LBBAP 和 LV 起搏(LOT-aCRT)的患者和接受传统双心室起搏(BVP-aCRT)的患者。
共有 21 名患者入组研究(LOT-aCRT 组 10 例,BVP-aCRT 组 11 例)。在 LOT-aCRT 组中,BVP 的 QRS 时限(QRSd)从基线时的 158.0±13.0 ms 缩小至 132.0±4.5 ms(P=0.019),并通过 LBBAP 进一步缩小至 123.0±5.7 ms(P<0.01)。在手术后,当 LOT-aCRT 植入并起作用时,QRSd 进一步变为 121.0±3.8 ms,但无显著变化(P>0.05)。在 BVP-aCRT 组中,BVP 可使 QRSd 从基线时的 176.7±19.7 ms 显著降低至 133.3±8.2 ms(P=0.011)。然而,与 LOT-aCRT 相比,BVP 在缩小 QRSd 方面没有优势,差异具有统计学意义(P<0.01)。在 9 个月的随访期间,两组患者的左心室射血分数(LVEF)和 NT-proBNP 水平均有所改善(均 P<0.01)。然而,与 BVP-aCRT 相比,LOT-aCRT 对这些参数的变化更为显著(P<0.01)。
该研究表明,LOT-aCRT 在有收缩性心力衰竭和 LBBB 的患者中具有临床可行性。LOT-aCRT 可显著缩小 QRSd,并改善 LV 功能。